Spots Global Cancer Trial Database for bclc stage c hepatocellular carcinoma
Every month we try and update this database with for bclc stage c hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | NCT04992143 | BCLC Stage C He... | TACE Tilelizumab Sorafenib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | NCT04442581 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... | Cabozantinib S-... Pembrolizumab | 18 Years - | University of Washington | |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | NCT04442581 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... | Cabozantinib S-... Pembrolizumab | 18 Years - | University of Washington | |
| Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients | NCT04736121 | Unresectable He... BCLC Stage A He... BCLC Stage B He... BCLC Stage C He... | Resin microsphe... | 18 Years - | Sirtex Medical | |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | NCT04605731 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Durvalumab Tremelimumab | 18 Years - | City of Hope Medical Center | |
| BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | NCT04777708 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... Refractory Hepa... | Nanoplexed Poly... Pembrolizumab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | NCT04204577 | BCLC Stage B He... BCLC Stage C He... | Apatinib Mesyla... | 18 Years - 80 Years | Chinese PLA General Hospital | |
| Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | NCT06172205 | BCLC Stage C He... Chemotherapy Ef... | intravenous FOL... HAIC-FOLFOX plu... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | NCT06172205 | BCLC Stage C He... Chemotherapy Ef... | intravenous FOL... HAIC-FOLFOX plu... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Liver Cancer and Immunotherapy in the Liquid Biopsy Era | NCT05810402 | Hepatocellular ... BCLC Stage B He... BCLC Stage C He... Immune Checkpoi... Liquid Biopsy | Liquid Biopsy | 18 Years - | University Hospital, Montpellier | |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | NCT05199285 | BCLC Stage B He... BCLC Stage C He... Locally Advance... Metastatic Hepa... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He... | Ipilimumab Nivolumab | 18 Years - | Academic and Community Cancer Research United | |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | NCT04442581 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... | Cabozantinib S-... Pembrolizumab | 18 Years - | University of Washington | |
| TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | NCT04992143 | BCLC Stage C He... | TACE Tilelizumab Sorafenib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | NCT04442581 | Advanced Hepato... BCLC Stage B He... BCLC Stage C He... | Cabozantinib S-... Pembrolizumab | 18 Years - | University of Washington |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
